Attached files

file filename
EX-32.2 - EX-32.2 - Paratek Pharmaceuticals, Inc.prtk-ex322_9.htm
EX-32.1 - EX-32.1 - Paratek Pharmaceuticals, Inc.prtk-ex321_11.htm
EX-31.2 - EX-31.2 - Paratek Pharmaceuticals, Inc.prtk-ex312_8.htm
EX-31.1 - EX-31.1 - Paratek Pharmaceuticals, Inc.prtk-ex311_6.htm
EX-23.1 - EX-23.1 - Paratek Pharmaceuticals, Inc.prtk-ex231_1172.htm
EX-21.1 - EX-21.1 - Paratek Pharmaceuticals, Inc.prtk-ex211_357.htm
EX-10.29 - EX-10.29 - Paratek Pharmaceuticals, Inc.prtk-ex1029_614.htm
EX-10.28 - EX-10.28 - Paratek Pharmaceuticals, Inc.prtk-ex1028_613.htm
EX-10.27 - EX-10.27 - Paratek Pharmaceuticals, Inc.prtk-ex1027_615.htm
EX-10.26 - EX-10.26 - Paratek Pharmaceuticals, Inc.prtk-ex1026_530.htm
EX-10.25 - EX-10.25 - Paratek Pharmaceuticals, Inc.prtk-ex1025_529.htm
EX-10.23 - EX-10.23 - Paratek Pharmaceuticals, Inc.prtk-ex1023_359.htm
EX-10.7 - EX-10.7 - Paratek Pharmaceuticals, Inc.prtk-ex107_358.htm
EX-10.6F - EX-10.6F - Paratek Pharmaceuticals, Inc.prtk-ex106f_356.htm
EX-10.6E - EX-10.6E - Paratek Pharmaceuticals, Inc.prtk-ex106e_355.htm
EX-5.1 - EX-5.1 - Paratek Pharmaceuticals, Inc.prtk-ex51_625.htm
EX-1.1 - EX-1.1 - Paratek Pharmaceuticals, Inc.prtk-ex11_626.htm
10-K - 10-K - Paratek Pharmaceuticals, Inc.prtk-10k_20161231.htm

Exhibit 23.2

Consent of Independent Registered

Public Accounting Firm

We consent to the incorporation by reference in Registration Statement Nos. 333-188171, 333-201458, 333-207441 and 333-215123 on Form S-3 and Registration Statement Nos. 333-135506, 333-150869, 333-157927, 333-157929, 333-160222, 333-164468, 333-172041, 333-180517, 333-187254, 333-194624, 333-201204, 333-205482 and 333-210053 on Form S-8 of our report dated March 9, 2016, on our audits of the consolidated financial statements of Paratek Pharmaceuticals, Inc. as of December 31, 2015 and for each of the two years in the period ended December 31, 2015, included in this Annual Report on Form 10-K of Paratek Pharmaceuticals, Inc. for the year ended December 31, 2016.

 

/s/ CohnReznick LLP

Vienna, Virginia

March 1, 2017